Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells

Abstract

Redirecting human T lymphocytes to the tumor-associated ganglioside GD2 generates effector cells with antimelanoma activity that should be testable in subjects with disease.